The Friendswood-based firm, known for its suite of molecular tests including DecisionDx-Melanoma and TissueCypher, maintains a focus on providing clinicians with actionable data for treatment planning. Management plans to deliver a comprehensive company overview, highlighting how its personalized diagnostic solutions aim to improve patient outcomes. Investors and interested parties can follow the session via a live audio webcast hosted on the company’s investor relations website, with a replay scheduled for release shortly after the broadcast concludes.